Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib

Autor: White, Maya N., Piper-Vallillo, Andrew J, Gardner, Rebecca M., Cunanan, Kristen, Neal, Joel W., Das, Millie, Padda, Sukhmani K., Ramchandran, Kavitha, Chen, Thomas T., Sequist, Lecia V., Piotrowska, Zofia, Wakelee, Heather A.

Publikováno v: In Clinical Lung Cancer May 2022 23(3):e210-e221

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Autor: White, Maya N, Piotrowska, Zofia, Stirling, Kevin, Liu, Stephen V, Banwait, Mandeep K, Cunanan, Kristen, Sequist, Lecia V, Wakelee, Heather A, Hausrath, Daniel, Neal, Joel W

Publikováno v: In Clinical Lung Cancer May 2021 22(3):201-209

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review.

Autor: Rahimy E; Department of Radiation Oncology, Stanford University, Palo Alto, California., Koong A; Department of Radiation Oncology, Stanford University, Palo Alto, California., Toesca D; Department of Radiation Oncology, Stanford University, Palo Alto, California., White MN; Department of Oncology, Stanford University, Palo Alto, California., Panjwani N; Department of Radiation Oncology, Stanford University, Palo Alto, California., Fisher G; Department of Oncology, Stanford University, Palo Alto, California., Chang D; Department of Radiation Oncology, Stanford University, Palo Alto, California., Pollom E; Department of Radiation Oncology, Stanford University, Palo Alto, California.

Publikováno v: Advances in radiation oncology [Adv Radiat Oncol] 2020 May 21; Vol. 5 (6), pp. 1188-1196. Date of Electronic Publication: 2020 May 21 (Print Publication: 2020).